Drugs / GK Activator (2)
last change Oct 2007 re-read 2 minutes ago

GK Activator (2)

Developed for
type 2 diabetes mellitus
Investigated by
Hoffmann-La Roche

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT00437606 Mar → Jun 2007 type 2 diabetes mellitus Hoffmann-La Roche Terminated No outcome recorded
Phase 1 NCT00388986 Oct 2006 → Jul 2007 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT00377442 Aug 2006 → Apr 2007 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT00368368 Jan 2006 → Aug 2007 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 24 trials
Phase 2 NCT00366379 Jul 2006 → Jun 2007 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00316758 Feb 2006 → Oct 2007 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00266253 Nov 2005 → Mar 2007 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00266240 Nov 2005 → May 2007 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as GK Activator (2) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00366379
7

NCT00377442

NCT00437606

NCT00368368

NCT00316758

NCT00266240

NCT00388986

NCT00266253

Action Activate “GK Activator (2)” NCT00266240
Route Oral oral GK Activator (2)” NCT00266240